🎉 M&A multiples are live!
Check it out!

Spero Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Spero Therapeutics and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Spero Therapeutics Overview

About Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.


Founded

2013

HQ

United States of America
Employees

32

Financials

LTM Revenue $42.8M

LTM EBITDA n/a

EV

-$9.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Spero Therapeutics Financials

Spero Therapeutics has a last 12-month revenue of $42.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Spero Therapeutics achieved revenue of $27.4M and an EBITDA of -$72.5M.

Spero Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Spero Therapeutics valuation multiples based on analyst estimates

Spero Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $96.7M $27.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA $25.8M -$72.5M XXX XXX XXX
EBITDA Margin 27% -265% XXX XXX XXX
Net Profit -$46.4M $22.8M XXX XXX XXX
Net Margin -48% 83% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Spero Therapeutics Stock Performance

As of April 15, 2025, Spero Therapeutics's stock price is $1.

Spero Therapeutics has current market cap of $39.2M, and EV of -$9.4M.

See Spero Therapeutics trading valuation data

Spero Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$9.4M $39.2M XXX XXX XXX XXX $-1.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Spero Therapeutics Valuation Multiples

As of April 15, 2025, Spero Therapeutics has market cap of $39.2M and EV of -$9.4M.

Spero Therapeutics's trades at -0.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Spero Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Spero Therapeutics and 10K+ public comps

Spero Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$9.4M XXX XXX XXX
EV/Revenue -0.3x XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Spero Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Spero Therapeutics Valuation Multiples

Spero Therapeutics's NTM/LTM revenue growth is -49%

Spero Therapeutics's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $3.1M for the same period.

Over next 12 months, Spero Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Spero Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Spero Therapeutics and other 10K+ public comps

Spero Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -72% XXX XXX XXX XXX
EBITDA Margin -265% XXX XXX XXX XXX
EBITDA Growth -381% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -314% XXX XXX XXX XXX
Revenue per Employee $0.9M XXX XXX XXX XXX
Opex per Employee $3.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 87% XXX XXX XXX XXX
R&D Expenses to Revenue 353% XXX XXX XXX XXX
Opex to Revenue 365% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Spero Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Spero Therapeutics M&A and Investment Activity

Spero Therapeutics acquired  XXX companies to date.

Last acquisition by Spero Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Spero Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Spero Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Spero Therapeutics

When was Spero Therapeutics founded? Spero Therapeutics was founded in 2013.
Where is Spero Therapeutics headquartered? Spero Therapeutics is headquartered in United States of America.
How many employees does Spero Therapeutics have? As of today, Spero Therapeutics has 32 employees.
Who is the CEO of Spero Therapeutics? Spero Therapeutics's CEO is Mr. Satyavrat Shukla, C.F.A..
Is Spero Therapeutics publicy listed? Yes, Spero Therapeutics is a public company listed on NAS.
What is the stock symbol of Spero Therapeutics? Spero Therapeutics trades under SPRO ticker.
When did Spero Therapeutics go public? Spero Therapeutics went public in 2017.
Who are competitors of Spero Therapeutics? Similar companies to Spero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Spero Therapeutics? Spero Therapeutics's current market cap is $39.2M
What is the current revenue of Spero Therapeutics? Spero Therapeutics's last 12-month revenue is $42.8M.
What is the current EV/Revenue multiple of Spero Therapeutics? Current revenue multiple of Spero Therapeutics is -0.2x.
What is the current revenue growth of Spero Therapeutics? Spero Therapeutics revenue growth between 2023 and 2024 was -72%.
Is Spero Therapeutics profitable? Yes, Spero Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.